RLAY Stock Forecast & Price Target

Relay Therapeutics is attractive because its Dynamo platform is producing differentiated clinical data in difficult targets, especially zovegalisib, where the Phase 2 ReInspire study showed a 65% volumetric response rate across all doses, only 15% grade 3+ treatment-related adverse events, and no rash or stomatitis at 100mg and 300mg BID. The company also has a compelling balance sheet, ending 2Q26 with $910.9M in cash and an expected runway into 2029, which should support multiple catalysts without near-term financing pressure. With the stock carrying 24.51% short interest, ongoing Phase 3 breast cancer work, and a regulatory/data update in vascular anomalies by end-2026, the setup leaves room for a meaningful rerating if the next readouts confirm the current efficacy and tolerability profile.

Relay Therapeutics is exposed to substantial clinical risk because its drug candidates may fail to demonstrate sufficient efficacy or safety in current or future trials, and any setback would directly undermine the investment case. Its dependence on FDA and other regulatory approvals adds another layer of uncertainty, since delays or denials could stall commercialization and pressure the share price, while the oncology market remains highly competitive against larger, better-resourced biotech and pharmaceutical peers. Financially, the company is likely to need additional equity financing through a secondary offering to fund development, which would create dilution risk for existing shareholders.